Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 57 of 182 for:    carfilzomib OR pr-171

B-Cell Targeted Carfilzomib Desensitization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02442648
Recruitment Status : Recruiting
First Posted : May 13, 2015
Last Update Posted : August 8, 2018
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
E. Steve Woodle, University of Cincinnati

Brief Summary:
The primary purpose of this study is to provide a preliminary evaluation of the safety and potential efficacy of carfilzomib in reducing HLA antibody levels in highly sensitized kidney transplant candidates.

Condition or disease Intervention/treatment Phase
Transplants and Implants Drug: Carfilzomib Drug: Rituximab Phase 1

Detailed Description:
This study is a non-randomized, open label, iterative pilot study. The duration of study will include a 16 month enrollment period and 5 to 6 months of follow-up. A total of 32 patients, male and female, between the ages 18 to 65 will be enrolled.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation
Study Start Date : December 2014
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A (5-8 patients) - Carfilzomib
Two cycles of carfilzomib desensitization given.
Drug: Carfilzomib
Carfilzomib will be administered for desensitization per study protocol.
Other Name: Krypolis

Experimental: Group B (5-8 patients) - Carfilzomib/plasmapheresis
Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
Drug: Carfilzomib
Carfilzomib will be administered for desensitization per study protocol.
Other Name: Krypolis

Experimental: Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis
1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
Drug: Carfilzomib
Carfilzomib will be administered for desensitization per study protocol.
Other Name: Krypolis

Drug: Rituximab
Rituximab will be administered for desensitization per study protocol.
Other Name: Rituxan

Experimental: Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis
1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
Drug: Carfilzomib
Carfilzomib will be administered for desensitization per study protocol.
Other Name: Krypolis

Drug: Rituximab
Rituximab will be administered for desensitization per study protocol.
Other Name: Rituxan




Primary Outcome Measures :
  1. Safety of carfilzomib will be assessed by incidence of grade 3 and above non-hematologic toxicities, incidence of grade 4 hematologic toxicities and incidence of all grades of peripheral neuropathy [ Time Frame: 6 months ]
    The primary objective of the proposed study is to evaluate the safety of carfilzomib alone and in combination with plasmapheresis, with or without rituximab, for desensitization in highly sensitized kidney transplant candidates. Safety will be assessed by overall safety of carfilzomib when used in the desensitization setting, incidence of grade 3 and above non-hematologic toxicities, incidence of grade 4 hematologic toxicities and incidence of all grades of peripheral neuropathy.


Secondary Outcome Measures :
  1. Efficacy of carfilzomib [ Time Frame: 6 months ]
    The primary objective of the proposed study is to evaluate the efficacy of carfilzomib alone and in combination with plasmapheresis, with or without rituximab, for desensitization in highly sensitized kidney transplant candidates. Efficacy will be measured by percent reduction in immunodominant DSA (iDSA) [highest titer DSA (MFI)] and/or immunodominant antibody (iAb) from pre-treatment to 48 hours after the last plasmapheresis treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is between 18 and 65 years of age, inclusive.
  2. Voluntary written informed consent.
  3. Female subject is either postmenopausal for at least 1 year prior to initiation of study treatment, is surgically sterilized, or if of childbearing potential, agrees to practice 2 effective methods of contraception through 3 months after the last dose of carfilzomib.
  4. Male subjects, even if surgically sterilized (i.e. status post-vasectomy) must agree to 1 effective contraception.
  5. Patient with eligible living donor will have: 1) positive cytotoxic crossmatch, or 2) moderate to strongly positive T or B cell flow cytometry crossmatch (with confirmed donor-specific antibodies (DSAs) on solid-phase assay at screening, or 3) > 2 low to moderate level DSAs (DSA value from 1500 - 8000 MFI).
  6. LVEF ≥ 45% within 3 months of evaluation.
  7. Patient that is on the kidney transplant waiting list awaiting a deceased donor transplant and has a current or peak cytotoxic or calculated panel reactive antibody (PRA) > 30%.
  8. Patient must have no known contraindications to treatment with carfilzomib or rituximab.
  9. Review of pre-transplant medical clearance by the patient's dialysis nephrologist or transplant nephrologist or treating physician to assure the patient is medically acceptable for study entry.
  10. Patient must be vaccinated against hepatitis B virus.

Exclusion Criteria:

  1. Patient has significant neuropathy (Grades 3 - 4, or Grade 2 with pain) by CTCAE criteria within 14 days before enrollment.
  2. Myocardial infarction within 6 months prior to enrollment or has ADQI Heart Failure in ESRD Classification System Class 2NR or greater (Appendix B), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  3. Patient has received other investigational drugs within 14 days prior to initiation of study treatment.
  4. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  5. Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of: 1) complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, 2) an in situ malignancy, 3) low-risk prostate cancer after curative therapy, or 4) any cancer with a cure rate ≥ 99%.
  6. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
  7. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  8. Patients with a hemoglobin count <8 g/dL (80 g/L) (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines), absolute neutrophil count < 1,000/mm3 or platelet count < 75,000/mm3 within 14 days of consent.
  9. Patients who are anti-HIV-positive, or HBsAg-positive, or anti-HCV positive with a detectable HCV viral load on testing performed within one year of consent.
  10. Patients with current or recent severe systemic infections requiring treatment (systemic antibiotics, antivirals, or antifungals) within the 2 weeks prior to initiation of study treatment.
  11. Receipt of a live vaccine within 4 weeks prior to initiation of study treatment.
  12. Evidence of severe liver disease by medical history or physical exam with abnormal liver profile (aspartate aminotransferase [AST], alanine aminotransferase [ALT] or total bilirubin > 1.5 times upper limit of normal [ULN]) on testing performed within 30 days of consent.
  13. Female subject is pregnant or breast-feeding.
  14. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
  15. Patient is not yet on dialysis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02442648


Contacts
Layout table for location contacts
Contact: E. Steve Woodle, MD 513-558-6001 woodlees@uc.edu

Locations
Layout table for location information
United States, Ohio
The Christ Hospital Recruiting
Cincinnati, Ohio, United States, 45219
Contact: E. Steve Woodle, MD    513-558-6001    Woodlees@uc.edu   
Principal Investigator: E. Steve Woodle, MD         
Sub-Investigator: Adele Rike-Shields, PharmD         
Sub-Investigator: Michael Cardi, MD         
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45267
Contact: E. Steve Woodle, MD    513-558-6001    Woodlees@uc.edu   
Principal Investigator: E. Steve Woodle, MD         
Sub-Investigator: James Driscoll, MD         
Sub-Investigator: Rita R Alloway, PharmD         
Sub-Investigator: Alin Girnita, MD         
Sub-Investigator: Paul Brailey         
Sponsors and Collaborators
E. Steve Woodle
Amgen
Investigators
Layout table for investigator information
Principal Investigator: E. Steve Woodle, MD University of Cincinnati

Layout table for additonal information
Responsible Party: E. Steve Woodle, Director, Solid Organ Transplantation, University of Cincinnati
ClinicalTrials.gov Identifier: NCT02442648     History of Changes
Other Study ID Numbers: Carfilzomib
First Posted: May 13, 2015    Key Record Dates
Last Update Posted: August 8, 2018
Last Verified: August 2018
Keywords provided by E. Steve Woodle, University of Cincinnati:
Renal Transplantation
Carfilzomib
Kyprolis
Desensitization
Additional relevant MeSH terms:
Layout table for MeSH terms
Rituximab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents